CN121102193A - 乳酸乙酯在酒精性相关肝病的应用 - Google Patents

乳酸乙酯在酒精性相关肝病的应用

Info

Publication number
CN121102193A
CN121102193A CN202410755468.5A CN202410755468A CN121102193A CN 121102193 A CN121102193 A CN 121102193A CN 202410755468 A CN202410755468 A CN 202410755468A CN 121102193 A CN121102193 A CN 121102193A
Authority
CN
China
Prior art keywords
ethyl lactate
liver
alcoholic
liver disease
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410755468.5A
Other languages
English (en)
Chinese (zh)
Inventor
李于
张翠英
肖冬光
蒋洋
崔奥媛
赵久香
林良才
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin University of Science and Technology
Shanghai Institute of Nutrition and Health of CAS
Original Assignee
Tianjin University of Science and Technology
Shanghai Institute of Nutrition and Health of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin University of Science and Technology, Shanghai Institute of Nutrition and Health of CAS filed Critical Tianjin University of Science and Technology
Priority to CN202410755468.5A priority Critical patent/CN121102193A/zh
Priority to PCT/CN2024/143404 priority patent/WO2025256111A1/fr
Publication of CN121102193A publication Critical patent/CN121102193A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
    • C12G3/00—Preparation of other alcoholic beverages
    • C12G3/04—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202410755468.5A 2024-06-12 2024-06-12 乳酸乙酯在酒精性相关肝病的应用 Pending CN121102193A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410755468.5A CN121102193A (zh) 2024-06-12 2024-06-12 乳酸乙酯在酒精性相关肝病的应用
PCT/CN2024/143404 WO2025256111A1 (fr) 2024-06-12 2024-12-27 Utilisation de lactate d'éthyle pour traiter une lésion hépatique et une maladie hépatique associée à l'alcool

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202410755468.5A CN121102193A (zh) 2024-06-12 2024-06-12 乳酸乙酯在酒精性相关肝病的应用

Publications (1)

Publication Number Publication Date
CN121102193A true CN121102193A (zh) 2025-12-12

Family

ID=97940231

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202410755468.5A Pending CN121102193A (zh) 2024-06-12 2024-06-12 乳酸乙酯在酒精性相关肝病的应用

Country Status (2)

Country Link
CN (1) CN121102193A (fr)
WO (1) WO2025256111A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1030506C (zh) * 1994-04-10 1995-12-13 吉林市酿酒总厂 营养型配制酒

Also Published As

Publication number Publication date
WO2025256111A1 (fr) 2025-12-18

Similar Documents

Publication Publication Date Title
Liang et al. Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling
Chenxu et al. Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving Toll-like receptor 4 and oxidative stress
US10702519B2 (en) Use of methoxatin, derivative and/or salt thereof in Sjogren's syndrome and pharmaceutical composition
CA2611389C (fr) Composition destinee a moderer le metabolisme de l'alcool et a reduire le risque de maladies induites par l'alcool
CN102355898B (zh) 能量消耗促进剂
CN111388490B (zh) 一种具有防治酒精性脂肪肝功能的人参皂苷组合物
US20080038321A1 (en) Prophylactic/therapeutic compositions for liver diseases
CN105943530B (zh) 铁死亡抑制剂在制备治疗铁过载疾病的药物中的应用
AU2022319030A1 (en) Paraxanthine-based caffeine substitute compositions and method of use thereof in slow caffeine metabolizers
US20230106742A1 (en) Composition for inducing browning, containing milk exosomes
CN121102193A (zh) 乳酸乙酯在酒精性相关肝病的应用
EP4640224A1 (fr) Composition pharmaceutique contenant un inhibiteur du transporteur de sodium-glucose-2 et un bloqueur du récepteur de l'angiotensine ii pour la prévention ou le traitement d'une stéatose hépatique non alcoolique
KR20220076653A (ko) 노봉방 추출물을 유효성분으로 포함하는 비만의 예방 또는 치료용 약학적 조성물
CN115607546A (zh) Isarubrolone C、包含Isarubrolone C的药物组合物及应用
CN108379272A (zh) 猪去氧胆酸在制备减肥以及治疗或预防肥胖并发症药物中的应用
WO2012074184A1 (fr) Composition pharmaceutique pour empêcher ou traiter l'obésité, comprenant du sphingosine-1-phosphate ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif
KR101613252B1 (ko) 아르기나아제 억제제를 함유하는 비만 및 지방간 예방 또는 치료용 조성물
US9693982B2 (en) Composition for amelioration of hypoalbuminemia
WO2007069744A1 (fr) Composition pour prévenir/améliorer un syndrome métabolique
US20110301106A1 (en) Use of Icariside II in Manufacture of Products for Preventing or Treating Male or Female Sexual Dysfunction
CN121370888A (zh) 一种用于治疗代谢综合征的内源性小分子代谢物
JP6374682B2 (ja) 筋萎縮抑制剤
KR20080094466A (ko) 대사증후군 치료용 약제 조성물
US20250057864A1 (en) Composition for improving exercise performance comprising gypenoside compound as active ingredient
CN121489926A (zh) 马尿酸在激活棕色脂肪组织产热及防治肥胖中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination